Compare Quantumscape Corp (QS) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantumscape Corp vs Sana Biotechnology Inc — how do they compare? Quantumscape Corp trades at $5.27 (market cap $3.44B), while Sana Biotechnology Inc trades at $3.24 (market cap $1.03B). The key difference: Quantumscape Corp is far larger — about 3.3× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals.
| QS | SANA | |
|---|---|---|
Market Cap | $3.44B | $1.03B |
Sector | Consumer Cyclical | Health |
52-Week High | $18.44 | $5.92 |
52-Week Low | $4.89 | $2.68 |
Enterprise Value | $2.65B | $946.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QuantumScape trades at $5.59, up 2.01% today but near 52-week lows, with a bearish technical signal from moving averages. The company is pre-revenue, reporting a net loss of $435.05M in 2025, negative ROE of -39.08%, and cash burn from operations. Recent news highlights insider sales and delayed commercialization timelines, with solid-state battery production not expected until 2029.
Outlook remains speculative with high execution risk; analyst consensus is cautious (0% buy, 73% hold, 27% sell). Investment hinges on successful battery commercialization by 2029, but competition and funding needs pose significant threats to shareholder value amid persistent losses.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
